The international COVID-19 vaccination dataset that we make available on this page is updated each morning (London time), using the most recent official numbers from governments and health ministries worldwide up to the previous day. The population estimates we use to calculate per-capita metrics are all based on the last revision of the United Nations World Population Prospects. A full list of our country-specific sources is available at the bottom of this page, and we also answer frequently-asked questions there.
In our Data Explorer you can see all of our data on COVID-19 vaccinations (doses administered, people with at least 1 dose, and people fully vaccinated).
→ Open the Data Explorer in a new tab.
Select a group of countries at once: all European countries, 30 largest countries; EU; Americas; OECD.
To bring this pandemic to an end, a large share of the world needs to be immune to the virus. The safest way to achieve this is with a vaccine. Vaccines are a technology that humanity has often relied on in the past to bring down the death toll of infectious diseases.
Within less than 12 months after the beginning of the COVID-19 pandemic, several research teams rose to the challenge and developed vaccines that protect from SARS-CoV-2, the virus that causes COVID-19.
Now the challenge is to make these vaccines available to people around the world. It will be key that people in all countries — not just in rich countries — receive the required protection. To track this effort we at Our World in Data are building the international COVID-19 vaccination dataset that we make available on this page. It is updated each morning, with the most recent official numbers up to the previous day.
- Data sources: at the end of this page you find a detailed list of all our country-specific sources.
- Open access: as with all of our data, we are making this dataset openly available, so that everyone can check and use the data that we bring together. You find the vaccination data in our daily-updated repository on GitHub.
Country-by-country data on COVID-19 vaccinations
This page has a number of charts on vaccination. In the box below you can select any country you are interested in — or several, if you want to compare countries.
All charts on this page will then show data for the countries that you selected.
The following charts show the breakdown of vaccinations by those that have been partly or fully vaccinated. A person is considered partly vaccinated if they have received only one dose of a 2-dose vaccine protocol. A person is considered fully vaccinated if they have received a single-dose vaccine or both doses of a two-dose vaccine.
This data is only available for countries which report the breakdown of doses administered by first and second doses.
The following chart shows the daily number of COVID-19 vaccination doses administered per 100 people. This is shown as the rolling seven-day average. Note that this is counted as a single dose, and may not equal the total number of people vaccinated, depending on the specific dose regime (e.g. people receive multiple doses).
The following map and chart show the number of COVID-19 vaccination doses administered per 100 people within a given population. Note that this is counted as a single dose, and may not equal the total number of people vaccinated, depending on the specific dose regime as several available COVID vaccines require multiple doses.
The following chart shows the total number of COVID-19 vaccination doses administered. Note that this is counted as a single dose, and may not equal the total number of people vaccinated, depending on the specific dose regime (e.g. people receive multiple doses).
The following chart shows the share of the total population that has received at least one dose of the COVID-19 vaccine. This may not equal the share that are fully vaccinated if the vaccine requires two doses. If a person receives the first dose of a 2-dose vaccine, this metric goes up by 1. If they receive the second dose, the metric stays the same.
The following chart shows the total number of people that have received at least one dose of the COVID-19 vaccine. This may not equal the number that are fully vaccinated if the vaccine requires two doses. If a person receives the first dose of a 2-dose vaccine, this metric goes up by 1. If they receive the second dose, the metric stays the same.
The following chart shows the share of the total population that has been fully vaccinated against COVID-19. This represents the share that have received all doses prescribed by the vaccination protocol. If a person receives the first dose of a 2-dose vaccine, this metric stays the same. If they receive the second dose, the metric goes up by 1.
This data is only available for countries which report the breakdown of doses administered by first and second doses.
The following chart shows the total number of people that have been fully vaccinated against COVID-19. This represents the number that have received all doses prescribed by the vaccination protocol. If a person receives the first dose of a 2-dose vaccine, this metric stays the same. If they receive the second dose, the metric goes up by 1.
This data is only available for countries which report the breakdown of doses administered by first and second doses.
The following chart shows the cumulative number of doses administered, broken down by vaccine manufacturer.
This is only available for a select number of countries which report the necessary data.
This interactive chart maps government policies on COVID-19 vaccination. Note that this only tracks policies on the availability of vaccinations. It does not track the number of people who have been vaccinated.
Countries are grouped into six categories:
- No availability
- Availability for ONE of following: key workers/ clinically vulnerable groups / elderly groups
- Availability for TWO of following: key workers/ clinically vulnerable groups / elderly groups
- Availability for ALL of following: key workers/ clinically vulnerable groups / elderly groups
- Availability for all three plus partial additional availability (select broad groups/ages)
- Universal availability
Vaccination policy data is sourced from the Oxford Coronavirus Government Response Tracker
This data on vaccination policies is sourced from the Oxford Coronavirus Government Response Tracker (OxCGRT).
This resource is published by researchers at the Blavatnik School of Government at the University of Oxford: Thomas Hale, Anna Petherik, Beatriz Kira, Noam Angrist, Toby Phillips and Samuel Webster.
The tracker presents data collected from public sources by a team of over one hundred Oxford University students and staff from every part of the world.
The data presented here is taken directly from the OxCGRT project; Our World in Data do not track policy responses ourselves, and do not make additions to the tracker dataset.
These charts are regularly updated based on the latest version of the response tracker.
OxCGRT is an ongoing collation project of live data. If you see any inaccuracies in the underlying data, or for specific feedback on the analysis or another aspect of the project please contact OxCGRT team. See the tracker’s notes and guidance on data quality.
The Imperial College London YouGov Covid-19 Behaviour Tracker Data Hub gathers global insights on people’s behaviors in response to COVID-19. This survey covers public behaviors and attitudes ranging from mask-wearing to self-isolation, social distancing, symptoms and testing.
The following chart shows monthly data on the willingness of unvaccinated individuals to receive the COVID-19 vaccine.
Data represents the share of respondents who have not received a COVID-19 vaccine and who agree with the following statement: “If a COVID-19 vaccine were made available to me this week, I would definitely get it.” Respondents were presented with a 1 to 5 scale, ranging from “Strongly agree” (1) to “Strongly disagree” (5). We consider responses of 1 or 2 to be in agreement with the statement.
The speed at which the first COVID-19 vaccines were developed was extraordinary. We have previously looked into the history of vaccine development. The measles vaccine was found relatively rapidly: it took only 10 years from the discovery of the pathogen to the development of the first vaccine. But for typhoid it took more than a century, and for some diseases for which we’ve known the pathogens for more than a century (like malaria) we still haven’t found an effective vaccine.
The development of a vaccine against COVID-19 has been much faster than the development of any other vaccine. Within less than a year several successful vaccines have already been announced and were approved for use in some countries.
The hope is that even more manufacturers develop vaccines for COVID-19. This will be important because eventually a very large share of the world population needs to receive a COVID-19 vaccine.
Several institutions maintain websites on which they list COVID-19 candidate vaccines that are currently being developed:
- The London School of Hygiene & Tropical Medicine Vaccine Tracker is updated weekly and shows the current stage of each development.
- WHO Vaccine Tracker – The WHO is tracking the COVID-19 candidate vaccines that are under development.
- Milken Institute Vaccine Tracker – The Milken Institute publishes, and regularly updates a tracker of possible treatments and vaccines for COVID-19 that scientists are currently working on.
- New York Times – The NYT tracker includes brief summaries of each development.
You can download the full dataset alongside the detailed sources on GitHub.
Vaccination against COVID-19 has now started in 191 locations.
Location | Source | Last observation date | Vaccines |
---|---|---|---|
Afghanistan | Government of Afghanistan | Apr. 22, 2021 | Oxford/AstraZeneca |
Albania | Ministry of Health | May. 5, 2021 | Oxford/AstraZeneca, Pfizer/BioNTech, Sinovac, Sputnik V |
Algeria | Ministry of Health | Feb. 19, 2021 | Sputnik V |
Andorra | Government of Andorra | May. 3, 2021 | Oxford/AstraZeneca, Pfizer/BioNTech |
Angola | Ministry of Health | Apr. 23, 2021 | Oxford/AstraZeneca |
Anguilla | Ministry of Health | Apr. 22, 2021 | Oxford/AstraZeneca |
Antigua and Barbuda | Ministry of Health | Apr. 22, 2021 | Oxford/AstraZeneca |
Argentina | Ministry of Health | May. 5, 2021 | Oxford/AstraZeneca, Sinopharm/Beijing, Sputnik V |
Armenia | Ministry of Health | Mar. 31, 2021 | Sputnik V |
Aruba | Government of Aruba | May. 5, 2021 | Pfizer/BioNTech |
Australia | Government of Australia via covidlive.com.au | May. 5, 2021 | Oxford/AstraZeneca, Pfizer/BioNTech |
Austria | Ministry of Health | May. 5, 2021 | Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech |
Azerbaijan | Government of Azerbaijan | May. 5, 2021 | Oxford/AstraZeneca, Sinovac |
Bahamas | Government of the Bahamas | Apr. 27, 2021 | Oxford/AstraZeneca |
Bahrain | Ministry of Health | May. 5, 2021 | Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sputnik V |
Bangladesh | Directorate General of Health Services | May. 5, 2021 | Oxford/AstraZeneca |
Barbados | Ministry of Health | May. 3, 2021 | Oxford/AstraZeneca |
Belarus | Ministry of Health | Apr. 23, 2021 | Sputnik V |
Belgium | Sciensano | May. 5, 2021 | Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech |
Belize | Ministry of Health | May. 3, 2021 | Oxford/AstraZeneca |
Bermuda | Government of Bermuda | Apr. 26, 2021 | Pfizer/BioNTech |
Bhutan | Ministry of Health | May. 4, 2021 | Oxford/AstraZeneca |
Bolivia | Ministry of Health | May. 3, 2021 | Oxford/AstraZeneca, Sinopharm/Beijing, Sputnik V |
Bosnia and Herzegovina | Public Health Institute | Apr. 27, 2021 | Oxford/AstraZeneca, Pfizer/BioNTech, Sinovac, Sputnik V |
Botswana | Ministry of Health and Wellness | Apr. 30, 2021 | Oxford/AstraZeneca |
Brazil | Ministry of Health | May. 5, 2021 | Oxford/AstraZeneca, Sinovac |
Brunei | Ministry of Health | Apr. 23, 2021 | Oxford/AstraZeneca |
Bulgaria | Ministry of Health | May. 5, 2021 | Moderna, Oxford/AstraZeneca, Pfizer/BioNTech |
Cambodia | Ministry of Health | May. 5, 2021 | Oxford/AstraZeneca, Sinopharm/Beijing, Sinovac |
Cameroon | Medical Council | Apr. 29, 2021 | Sinopharm/Beijing |
Canada | Official data from provinces via covid19tracker.ca | May. 5, 2021 | Moderna, Oxford/AstraZeneca, Pfizer/BioNTech |
Cape Verde | Government of Cape Verde | Mar. 24, 2021 | Oxford/AstraZeneca |
Cayman Islands | Cayman Islands Government | May. 5, 2021 | Oxford/AstraZeneca, Pfizer/BioNTech |
Chile | Department of Statistics and Health Information | May. 5, 2021 | Pfizer/BioNTech, Sinovac |
China | National Health Commission | May. 5, 2021 | Sinopharm/Beijing, Sinopharm/Wuhan, Sinovac |
Colombia | Ministry of Health | May. 2, 2021 | Oxford/AstraZeneca, Pfizer/BioNTech, Sinovac |
Comoros | Ministry of Health | Apr. 21, 2021 | Oxford/AstraZeneca |
Congo | Government of the Republic of Congo | Apr. 14, 2021 | Sinopharm/Beijing, Sputnik V |
Costa Rica | Costa Rican Social Security Fund | May. 3, 2021 | Oxford/AstraZeneca, Pfizer/BioNTech |
Cote d’Ivoire | Ministry of Health and Public Hygiene | May. 4, 2021 | Oxford/AstraZeneca |
Croatia | Ministry of Health | May. 5, 2021 | Moderna, Oxford/AstraZeneca, Pfizer/BioNTech |
Curacao | Government of Curacao | May. 5, 2021 | Moderna, Pfizer/BioNTech |
Cyprus | Government of Cyprus | May. 1, 2021 | Pfizer/BioNTech |
Czechia | Ministry of Health | May. 5, 2021 | Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech |
Democratic Republic of Congo | Ministry of Health | Apr. 25, 2021 | Oxford/AstraZeneca |
Denmark | Statens Serum Institute | May. 4, 2021 | Moderna, Oxford/AstraZeneca, Pfizer/BioNTech |
Djibouti | Présidence de la République de Djibouti | Apr. 17, 2021 | Oxford/AstraZeneca |
Dominica | Government of Dominica | Apr. 28, 2021 | Oxford/AstraZeneca |
Dominican Republic | Ministry of Public Health | May. 5, 2021 | Oxford/AstraZeneca, Sinopharm/Beijing, Sinovac |
Ecuador | Government of Ecuador via Ecuacovid | May. 4, 2021 | Oxford/AstraZeneca, Pfizer/BioNTech, Sinovac |
Egypt | Ministry of Health | Apr. 18, 2021 | Oxford/AstraZeneca, Sinopharm/Beijing |
El Salvador | Ministry of Health | May. 4, 2021 | Oxford/AstraZeneca, Pfizer/BioNTech, Sinovac |
England | Government of the United Kingdom | May. 5, 2021 | Moderna, Oxford/AstraZeneca, Pfizer/BioNTech |
Equatorial Guinea | Ministry of Health | Apr. 28, 2021 | Sinopharm/Beijing |
Estonia | National Health Board | May. 5, 2021 | Moderna, Oxford/AstraZeneca, Pfizer/BioNTech |
Eswatini | Government of Eswatini | Apr. 25, 2021 | Oxford/AstraZeneca |
Ethiopia | Ministry of Health | May. 5, 2021 | Oxford/AstraZeneca |
Faeroe Islands | Government of the Faeroe Islands | Apr. 28, 2021 | Moderna, Pfizer/BioNTech |
Falkland Islands | Government of the Falkland Islands | Apr. 14, 2021 | Oxford/AstraZeneca |
Fiji | Ministry of Health | Apr. 16, 2021 | Oxford/AstraZeneca |
Finland | Finnish Institute for Health and Welfare | May. 5, 2021 | Moderna, Oxford/AstraZeneca, Pfizer/BioNTech |
France | Public Health France | May. 5, 2021 | Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech |
Gabon | Ministry of Health | Apr. 23, 2021 | Sinopharm/Beijing |
Gambia | Ministry of Health | Apr. 24, 2021 | Oxford/AstraZeneca |
Georgia | Government of Georgia | Apr. 30, 2021 | Oxford/AstraZeneca |
Germany | Robert Koch Institut | May. 5, 2021 | Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech |
Ghana | Government of Ghana | Apr. 30, 2021 | Oxford/AstraZeneca |
Gibraltar | Government of Gibraltar | May. 1, 2021 | Pfizer/BioNTech |
Greece | Ministry of Health | May. 5, 2021 | Moderna, Oxford/AstraZeneca, Pfizer/BioNTech |
Greenland | Government of Greenland | May. 4, 2021 | Pfizer/BioNTech |
Grenada | Government of Grenada | Apr. 29, 2021 | Oxford/AstraZeneca |
Guatemala | Ministry of Health | May. 5, 2021 | Moderna, Oxford/AstraZeneca |
Guernsey | Government of Guernsey | Apr. 20, 2021 | Oxford/AstraZeneca, Pfizer/BioNTech |
Guinea | National Health Security Agency | May. 3, 2021 | Sputnik V |
Guyana | Ministry of Health | Apr. 26, 2021 | Oxford/AstraZeneca |
Honduras | Government of Honduras | Apr. 9, 2021 | Moderna, Oxford/AstraZeneca |
Hong Kong | Government of Hong Kong | May. 5, 2021 | Pfizer/BioNTech, Sinovac |
Hungary | Government of Hungary | May. 5, 2021 | Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sputnik V |
Iceland | Directorate of Health | May. 5, 2021 | Moderna, Oxford/AstraZeneca, Pfizer/BioNTech |
India | Government of India | May. 5, 2021 | Covaxin, Oxford/AstraZeneca |
Indonesia | Ministry of Health | May. 4, 2021 | Oxford/AstraZeneca, Sinovac |
Iran | Government of Iran | May. 4, 2021 | Oxford/AstraZeneca, Sinopharm/Beijing, Sputnik V |
Iraq | Ministry of Health | Apr. 23, 2021 | Oxford/AstraZeneca, Sinopharm/Beijing |
Ireland | Heath Service Executive | May. 4, 2021 | Moderna, Oxford/AstraZeneca, Pfizer/BioNTech |
Isle of Man | Isle of Man Government | May. 5, 2021 | Oxford/AstraZeneca, Pfizer/BioNTech |
Israel (see FAQ) | Government of Israel | May. 5, 2021 | Moderna, Pfizer/BioNTech |
Italy | Extraordinary commissioner for the Covid-19 emergency | May. 5, 2021 | Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech |
Jamaica | Government of Jamaica | Apr. 13, 2021 | Oxford/AstraZeneca |
Japan | Prime Minister’s Office | May. 5, 2021 | Pfizer/BioNTech |
Jersey | Government of Jersey | May. 2, 2021 | Oxford/AstraZeneca, Pfizer/BioNTech |
Jordan | Government of Jordan | May. 4, 2021 | Pfizer/BioNTech, Sinopharm/Beijing |
Kazakhstan | Government of Kazakhstan | May. 5, 2021 | Sputnik V |
Kenya | Ministry of Health | Apr. 28, 2021 | Oxford/AstraZeneca, Sputnik V |
Kosovo | Ministry of Health | Apr. 23, 2021 | Oxford/AstraZeneca |
Kuwait | Ministry of Health | May. 4, 2021 | Pfizer/BioNTech |
Kyrgyzstan | Ministry of Health | Apr. 28, 2021 | Sinopharm/Beijing, Sputnik V |
Laos | Government of Laos | Apr. 26, 2021 | Sinopharm/Beijing, Sputnik V |
Latvia | National Health Service | May. 5, 2021 | Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech |
Lebanon | Government of Lebanon | May. 5, 2021 | Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sputnik V |
Lesotho | Government of Lesotho | Apr. 17, 2021 | Oxford/AstraZeneca |
Libya | Government of National Unity | Apr. 17, 2021 | Oxford/AstraZeneca, Sinovac, Sputnik V |
Liechtenstein | Federal Office of Public Health | May. 2, 2021 | Moderna, Pfizer/BioNTech |
Lithuania | Ministry of Health | May. 5, 2021 | Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech |
Luxembourg | Government of Luxembourg | May. 5, 2021 | Moderna, Oxford/AstraZeneca, Pfizer/BioNTech |
Macao | Government of Macao | May. 5, 2021 | Pfizer/BioNTech, Sinopharm/Beijing |
Malawi | Ministry of Health | Apr. 30, 2021 | Oxford/AstraZeneca |
Malaysia | Government of Malaysia | May. 3, 2021 | Pfizer/BioNTech, Sinovac |
Maldives | Presidency of the Maldives | May. 3, 2021 | Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing |
Mali | Ministry of Health | Apr. 25, 2021 | Oxford/AstraZeneca |
Malta | COVID-19 Malta Public Health Response Team | May. 5, 2021 | Moderna, Oxford/AstraZeneca, Pfizer/BioNTech |
Mauritania | Ministry of Health | Apr. 18, 2021 | Sinopharm/Beijing |
Mauritius | National Communication Committee on COVID-19 | Mar. 24, 2021 | Oxford/AstraZeneca |
Mexico | Secretary of Health | May. 4, 2021 | CanSino, Oxford/AstraZeneca, Pfizer/BioNTech, Sinovac, Sputnik V |
Moldova | Ministry of Health | May. 5, 2021 | Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing |
Monaco | National Council | Apr. 22, 2021 | Pfizer/BioNTech |
Mongolia | Ministry of Health via ikon.mn | May. 5, 2021 | Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sputnik V |
Montenegro | Government of Montenegro | May. 5, 2021 | Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sputnik V |
Montserrat | Government of Montserrat | Apr. 21, 2021 | Oxford/AstraZeneca |
Morocco | Ministry of Health | May. 5, 2021 | Oxford/AstraZeneca, Sinopharm/Beijing |
Mozambique | Deputy National Director of Public Health | Mar. 23, 2021 | Sinopharm/Beijing |
Myanmar | Ministry of Health | Mar. 31, 2021 | Oxford/AstraZeneca |
Namibia | Ministry of Health and Social Services | Apr. 28, 2021 | Oxford/AstraZeneca, Sinopharm/Beijing |
Nauru | Government of the Republic of Nauru | Apr. 15, 2021 | Oxford/AstraZeneca |
Nepal | Government of Nepal | Apr. 28, 2021 | Oxford/AstraZeneca, Sinopharm/Beijing |
Netherlands | National Institute for Public Health and the Environment | May. 2, 2021 | Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech |
New Zealand | Ministry of Health | May. 4, 2021 | Pfizer/BioNTech |
Nicaragua | Ministerio de Salud de la República de Nicaragua | Apr. 24, 2021 | Oxford/AstraZeneca, Sputnik V |
Niger | Government of Niger | Apr. 17, 2021 | Sinopharm/Beijing |
Nigeria | Government of Nigeria | May. 4, 2021 | Oxford/AstraZeneca |
North Macedonia | Government of North Macedonia | May. 5, 2021 | Oxford/AstraZeneca, Pfizer/BioNTech, Sputnik V |
Northern Cyprus | Ministry of Health | Apr. 23, 2021 | Oxford/AstraZeneca, Pfizer/BioNTech, Sinovac |
Northern Ireland | Government of the United Kingdom | May. 5, 2021 | Moderna, Oxford/AstraZeneca, Pfizer/BioNTech |
Norway | Norwegian Institute of Public Health | May. 5, 2021 | Moderna, Oxford/AstraZeneca, Pfizer/BioNTech |
Oman | Ministry of Health | May. 5, 2021 | Oxford/AstraZeneca, Pfizer/BioNTech |
Pakistan | National Command and Operation Centre | May. 5, 2021 | CanSino, Sinopharm/Beijing, Sinovac, Sputnik V |
Palestine (see FAQ) | Ministry of Health | Apr. 25, 2021 | Moderna, Oxford/AstraZeneca, Pfizer/BioNTech |
Panama | Ministry of Health | May. 5, 2021 | Oxford/AstraZeneca, Pfizer/BioNTech |
Papua New Guinea | Government of Papua New Guinea | Apr. 25, 2021 | Oxford/AstraZeneca |
Paraguay | Government of Paraguay | May. 2, 2021 | Sputnik V |
Peru | Ministry of Health | May. 5, 2021 | Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing |
Philippines | Government of the Philippines | May. 5, 2021 | Oxford/AstraZeneca, Sinovac |
Poland | Ministry of Health | May. 5, 2021 | Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech |
Portugal | Directorate General for Health via Data Science for Social Good | May. 5, 2021 | Moderna, Oxford/AstraZeneca, Pfizer/BioNTech |
Qatar | Ministry of Public Health | May. 5, 2021 | Pfizer/BioNTech |
Romania | Government of Romania | May. 5, 2021 | Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech |
Russia | Official data from local governments via gogov.ru | May. 5, 2021 | EpiVacCorona, Sputnik V |
Rwanda | Ministry of Health | May. 4, 2021 | Moderna, Oxford/AstraZeneca, Pfizer/BioNTech |
Saint Helena | Government of Saint Helena | Apr. 9, 2021 | Oxford/AstraZeneca |
Saint Kitts and Nevis | Government of Saint Kitts and Nevis | May. 4, 2021 | Oxford/AstraZeneca |
Saint Lucia | Ministry of Health | May. 4, 2021 | Oxford/AstraZeneca |
Saint Vincent and the Grenadines | Ministry of Health | May. 1, 2021 | Oxford/AstraZeneca |
Samoa | Ministry of Health | May. 3, 2021 | Oxford/AstraZeneca |
San Marino | Social Security Institute | May. 5, 2021 | Pfizer/BioNTech, Sputnik V |
Sao Tome and Principe | Ministry of Health | Mar. 29, 2021 | Oxford/AstraZeneca |
Saudi Arabia | Saudi Health Council | May. 5, 2021 | Oxford/AstraZeneca, Pfizer/BioNTech |
Scotland | Government of the United Kingdom | May. 5, 2021 | Moderna, Oxford/AstraZeneca, Pfizer/BioNTech |
Senegal | Ministry of Health | May. 4, 2021 | Sinopharm/Beijing |
Serbia | Government of Serbia | May. 5, 2021 | Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sputnik V |
Seychelles | Extended Programme for Immunisation | May. 3, 2021 | Oxford/AstraZeneca, Sinopharm/Beijing |
Sierra Leone | Ministry of Health and Sanitation | May. 1, 2021 | Oxford/AstraZeneca |
Singapore | Ministry of Health | Apr. 18, 2021 | Moderna, Pfizer/BioNTech |
Slovakia | Ministry of Health | May. 5, 2021 | Pfizer/BioNTech |
Slovenia | National Institute of Public Health via Sledilnik | May. 5, 2021 | Oxford/AstraZeneca, Pfizer/BioNTech |
Solomon Islands | Government of the Solomon Islands | Apr. 27, 2021 | Oxford/AstraZeneca |
Somalia | Federal Government of Somalia | Apr. 17, 2021 | Oxford/AstraZeneca, Sinopharm/Beijing |
South Africa | Ministry of Health | May. 5, 2021 | Johnson&Johnson |
South Korea | Korea Centers for Disease Control and Prevention | May. 5, 2021 | Oxford/AstraZeneca, Pfizer/BioNTech |
South Sudan | Government of South Sudan | Apr. 15, 2021 | Oxford/AstraZeneca |
Spain | Ministry of Health | May. 5, 2021 | Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech |
Sri Lanka | Ministry of Health’s Epidemiology Unit | May. 5, 2021 | Oxford/AstraZeneca, Sinopharm/Beijing |
Sudan | Federal Ministry of Health | Apr. 23, 2021 | Oxford/AstraZeneca |
Suriname | Government of Suriname | May. 4, 2021 | Oxford/AstraZeneca |
Sweden | Public Health Agency of Sweden | May. 5, 2021 | Oxford/AstraZeneca, Pfizer/BioNTech |
Switzerland | Federal Office of Public Health | May. 2, 2021 | Moderna, Pfizer/BioNTech |
Syria | Ministry of Health | Apr. 8, 2021 | Sputnik V |
Taiwan | Taiwan Centers for Disease Control | May. 5, 2021 | Oxford/AstraZeneca |
Thailand | Government of Thailand | May. 5, 2021 | Oxford/AstraZeneca, Sinovac |
Timor | Government of Timor-Leste | Apr. 14, 2021 | Oxford/AstraZeneca |
Togo | Government of Togo | Apr. 17, 2021 | Oxford/AstraZeneca |
Tonga | Government of Tonga | Apr. 26, 2021 | Oxford/AstraZeneca |
Trinidad and Tobago | Ministry of Health | May. 5, 2021 | Oxford/AstraZeneca |
Tunisia | Ministry of Health | May. 3, 2021 | Pfizer/BioNTech, Sinovac, Sputnik V |
Turkey | COVID-19 Vaccine Information Platform | May. 5, 2021 | Pfizer/BioNTech, Sinovac |
Turks and Caicos Islands | Ministry of Health | Apr. 11, 2021 | Pfizer/BioNTech |
Uganda | Ministry of Health | May. 2, 2021 | Oxford/AstraZeneca |
Ukraine | Ministry of Health | May. 5, 2021 | Oxford/AstraZeneca, Pfizer/BioNTech, Sinovac |
United Arab Emirates | National Emergency Crisis and Disaster Management Authority | May. 5, 2021 | Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sinopharm/Wuhan, Sputnik V |
United Kingdom | Government of the United Kingdom | May. 5, 2021 | Moderna, Oxford/AstraZeneca, Pfizer/BioNTech |
United States | Centers for Disease Control and Prevention | May. 5, 2021 | Johnson&Johnson, Moderna, Pfizer/BioNTech |
Uruguay | Ministry of Health | May. 5, 2021 | Oxford/AstraZeneca, Pfizer/BioNTech, Sinovac |
Uzbekistan | Government of Uzbekistan | Apr. 27, 2021 | Oxford/AstraZeneca |
Venezuela | Government of Venezuela | Apr. 12, 2021 | Sputnik V |
Vietnam | Government of Vietnam | May. 5, 2021 | Oxford/AstraZeneca |
Wales | Government of the United Kingdom | May. 5, 2021 | Moderna, Oxford/AstraZeneca, Pfizer/BioNTech |
Zambia | Government of Zambia | May. 5, 2021 | Oxford/AstraZeneca |
Zimbabwe | Ministry of Health | May. 4, 2021 | Sinopharm/Beijing |
Which population data are the per-capita metrics based on?
The population estimates we use to calculate per-capita metrics are all based on the last revision of the United Nations World Population Prospects. The exact values can be viewed in our GitHub repository. The United Nations estimates may not always reflect the latest censuses or national figures.
Can the value of per-capita metrics exceed 100%?
The population estimates we use to calculate per-capita metrics are all based on the last revision of the United Nations World Population Prospects. The United Nations estimates may not always reflect the latest censuses or national figures. Additionally, it’s important to bear in mind that in some territories vaccination coverage may include non-residents. For these reasons, per-capita metrics may exceed 100%.
My country has started vaccinating its population. Why is it missing from the charts?
Other countries that are not shown in our data may have also started vaccination campaigns. We’ll add them to our maps and charts as soon as numbers are verifiable based on public official sources. If you’re aware of an official source reporting numbers, please let us know using the “Feedback” button at the bottom of your screen.
Are participants in vaccine clinical trials included in your data?
We do not include participants in the vaccine arm of clinical trials, as this data is not available for many of the hundreds of trials currently taking place.
How do you report vaccinations performed in Israel and Palestine?
In our dataset and charts on COVID-19 vaccinations, we report vaccinations performed in Israel and Palestine separately.
The vaccination data is needed to understand how the pandemic is evolving. For this it is key to bring together the vaccination data with data on COVID-19 cases and COVID-19 deaths. Global health institutions that report on the pandemic are reporting these metrics separately:
- The World Health Organization reports the measures for Israel separately from Palestine in its data.
- Johns Hopkins University also reports Israel separately from Palestine in its data on cases & deaths of COVID-19, which has been used worldwide in the last year.
Reporting the data for Palestine and Israel separately also allows us to show their respective reported vaccination levels. It makes clear what the respective vaccination levels are, as reported by the Government of Israel and the Palestinian Ministry of Health.
Finally, our dataset on COVID-19 vaccinations is sourced from official data published by governments and ministries of health from countries around the world. This is also the case for Israel and Palestine. We show figures for Palestine and Israel separately, as they are reported separately by the Government of Israel and the Palestinian Ministry of Health.
The Populations Division of the United Nations reports population figures for countries around the world, and we are relying on their latest data (from their 2019 revision) for countries around the world of. They report a population of 8,655,541 people for Israel and a population of 5,101,416 people for Palestine.
The resulting shares of people vaccinated in Israel and Palestine can be seen in our COVID-19 Data Explorer.
Sign up for regular updates from Our World in Data
→ If you want to keep up-to-date with on our work on COVID-19, and the many other topics we cover you can sign up to our newsletter.